CEUS LI-RADS联合基于血清生物标志物的ASAP模型提高高危患者肝细胞癌诊断效能
本回顾性研究纳入366例患者的366个肝脏病灶,评估CEUS LI-RADS v2017联合基于年龄、性别、AFP和PIVKA-II构建的ASAP模型对高危患者肝细胞癌的诊断效能。将LR-3/4/M结节伴AFP>200 ng/mL或ASAP评分>0.5256且CA 19-9正常者重新分类为LR-5后,LR-5诊断HCC的敏感度从60.8%提高至86.9%,特异度和PPV无显著变化。
要点
- CEUS LI-RADS v2017各分类HCC发生率:LR-3为33.3%(4/12),LR-4为86.4%(38/44),LR-5为98.5%(191/194),LR-M为82.7%(81/98)。
- LR-3/4/M结节伴AFP>200 ng/mL重新分类为LR-5后,敏感度从60.8%升至70.7%(p<0.01),特异度94.2% vs 92.3%(p=1.00),PPV 98.5% vs 98.2%(p=0.86)。
- LR-3/4/M结节伴ASAP评分>0.5256且CA 19-9正常重新分类为LR-5后,敏感度进一步提高至86.9%(p<0.01),特异度92.3%和PPV 98.6%均无显著变化(均p>0.05)。
核心结论
- CEUS LI-RADS联合基于血清生物标志物的ASAP模型可提高LR-5诊断HCC的敏感度,对特异度和PPV影响较小。
研究设计与样本
- 回顾性研究,纳入366例患者的366个肝脏病灶,均行肝脏CEUS,按CEUS LI-RADS v2017分类,参考标准为组织病理学或综合影像及临床随访结果。
诊断标准与关键数值
- CEUS LI-RADS v2017分类LR-5诊断HCC的敏感度60.8%,特异度94.2%,PPV 98.5%。
- 标准2(LR-3/4/M结节伴AFP>200 ng/mL重新分类为LR-5)诊断HCC的敏感度70.7%,特异度92.3%,PPV 98.2%。
- 标准3(LR-3/4/M结节伴ASAP模型评分>0.5256且CA 19-9在正常范围重新分类为LR-5)诊断HCC的敏感度86.9%,特异度92.3%,PPV 98.6%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To assess the diagnostic efficacy of the CEUS LI-RADS combined with a model constructed on the basis of age, sex, AFP, and PIVKA-II (ASAP) for the diagnosis of HCC in high-risk patients.
METHODS: This retrospective study included 366 liver lesions from 366 patients who underwent liver CEUS. All liver lesions were characterized and categorized according to CEUS LI-RADS v2017. Two modified methods were applied: LR-3/4/M nodules accompanied by AFP > 200 ng/mL (Criterion 2) or ASAP model score > 0.5256 and CA 19-9 in the normal range (Criterion 3) were recategorized as LR-5. The reference criteria included histopathological or comprehensive imaging and the clinical follow-up results. The diagnostic performance was evaluated and compared by the sensitivity, specificity, PPV, and NPV.
RESULTS: The incidence of HCC in LR-3, LR-4, LR-5, and LR-M was 33.3% (4/12), 86.4% (38/44), 98.5% (191/194) and 82.7% (81/98), respectively. After using Criterion 2 compared to CEUS LI-RADS v2017, the sensitivity of the modified LR-5 for diagnosing HCC increased from 60.8% to 70.7% (p < 0.01) with little effect on its specificity (94.2% vs. 92.3%, p = 1.00) or PPV (98.5% vs. 98.2%, p = 0.86). After using Criterion 3, the sensitivity of the modified LR-5 for the diagnosis of HCC was further improved to 86.9% (p < 0.01), and its specificity and PPV were not significantly changed (92.3% and 98.6%, both p > 0.05).
CONCLUSION: CEUS LI-RADS combined with the serum biomarker-based ASAP model improved the sensitivity of LR-5 in diagnosing HCC with little effect on its specificity and PPV.
引用
- Wen R, Peng Y, Liang Y, et al. CEUS LI-RADS in Combination With the Serum Biomarker-Based ASAP Model Improves the Diagnostic Performance of HCC in High-Risk Patients. Ultrasound Med Biol. 2024. PMID: 39181805. doi:10.1016/j.ultrasmedbio.2024.08.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。